{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:43:51Z","timestamp":1785797031811,"version":"3.56.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300151"],"award-info":[{"award-number":["82300151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["KJS2344"],"award-info":[{"award-number":["KJS2344"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34111","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T03:55:18Z","timestamp":1720065318000},"page":"e34111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rediscovering hemostasis abnormalities in multiple myeloma: The new era"],"prefix":"10.1016","volume":"10","author":[{"given":"Yudie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-5261","authenticated-orcid":false,"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-6618","authenticated-orcid":false,"given":"Lu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.heliyon.2024.e34111_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med. J. Aust."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34111_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17474086.2021.1858790","article-title":"A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed\/refractory multiple myeloma","volume":"14","author":"Richard","year":"2021","journal-title":"Expert Rev. Hematol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib5","article-title":"Bleeding diathesis in multiple myeloma: a rare presentation of a dreadful emergency with management nightmare","volume":"13","author":"Rahman","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e34111_bib6","first-page":"1","article-title":"Thrombosis in multiple myeloma: mechanisms, risk assessment and management","author":"Jarchowsky","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34111_bib7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s12185-020-02954-2","article-title":"Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis","volume":"112","author":"Wang","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e34111_bib8","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13331","article-title":"Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma","volume":"104","author":"Hinterleitner","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5120967","article-title":"Analysis of coagulation abnormality in patients with multiple myeloma and its clinical significance","volume":"2022","author":"Pan","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.drudis.2019.11.008","article-title":"New generation drugs for treatment of multiple myeloma","volume":"25","author":"Alanazi","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e34111_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.5073.5073","article-title":"Retrospective analysis of thrombocytopenia in relapsed multiple myeloma patients","volume":"118","author":"Sousa","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34111_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0031-1297372","article-title":"Bleeding and thrombosis in multiple myeloma and related plasma cell disorders","volume":"37","author":"Coppola","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7861\/clinmed.2019-0326","article-title":"Images of the month 2: gastrointestinal bleeding with a large liver and a small spleen: a rare appearance of multiple myeloma","volume":"20","author":"Feng","year":"2020","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.14797\/mdcj-9-1-58","article-title":"Multiple myeloma presenting as pulmonary renal syndrome","volume":"9","author":"Szeto","year":"2013","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2003-40965","article-title":"The blood coagulation mechanism in multiple myeloma","volume":"29","author":"Zangari","year":"2003","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.heliyon.2024.e34111_bib17","series-title":"StatPearls [Internet]","article-title":"Hyperviscosity Syndrome","author":"Perez Rogers","year":"2023"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","article-title":"Hyperviscosity in plasma cell dyscrasias","volume":"55","author":"Kwaan","year":"2013","journal-title":"Clin. Hemorheol. Microcirc."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34111_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.revmed.2015.02.005","article-title":"[Hyperviscosity syndrome]","volume":"36","author":"Dumas","year":"2015","journal-title":"Rev. Med. Interne"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41467-023-37699-z","article-title":"Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma","volume":"14","author":"Kuang","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib21","first-page":"127","article-title":"Hemostatic abnormalities in multiple myeloma patients","volume":"19","author":"Gogia","year":"2018","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.heliyon.2024.e34111_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-015-0136-2","article-title":"The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma","volume":"8","author":"Jeong","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000345418","article-title":"Specific binding of paraprotein to platelet receptors as a cause of platelet dysfunction in monoclonal gammopathies","volume":"130","author":"Djunic","year":"2013","journal-title":"Acta Haematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/17843286.2023.2265650","article-title":"Acquired factor X deficiency in a multiple myeloma without amyloidosis: a case report","volume":"78","author":"Coussee","year":"2023","journal-title":"Acta Clin. Belg."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34111_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230249","article-title":"Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis","volume":"12","author":"Reynolds","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib26","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1055\/s-0039-1683969","article-title":"Interference of monoclonal gammopathy with fibrinogen assay producing spurious dysfibrinogenemia","volume":"3","author":"Martini","year":"2019","journal-title":"TH Open"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000160182","article-title":"Acquired dysfibrinogenemia secondary to multiple myeloma","volume":"120","author":"Kotl\u00edn","year":"2008","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-020-02874-1","article-title":"Acquired dysfibrinogenemia: monoclonal \u03bb-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation","volume":"112","author":"Arai","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34111_bib29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/17474086.2016.1194750","article-title":"A review of the venous thrombotic issues associated with multiple myeloma","volume":"9","author":"Fotiou","year":"2016","journal-title":"Expert Rev. Hematol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34111_bib30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e34111_bib31","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020007488","article-title":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors","volume":"137","author":"Dunbar","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaccao.2023.01.009","article-title":"Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer","volume":"5","author":"Feldman","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1160\/TH14-06-0513","article-title":"Adipokines at the crossroad between obesity and cardiovascular disease","volume":"113","author":"Molica","year":"2015","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.heliyon.2024.e34111_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8095926","article-title":"Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity","volume":"2017","author":"El Husseny","year":"2017","journal-title":"J. Diabetes Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11239-017-1528-7","article-title":"Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians","volume":"44","author":"Vazquez-Garza","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34111_bib36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front. Immunol."},{"issue":"1 Suppl 1","key":"10.1016\/j.heliyon.2024.e34111_bib38","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/j.seminhematol.2005.11.003","article-title":"Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders","volume":"43","author":"Federici","year":"2006","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1538-7836.2008.02917.x","article-title":"Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?","volume":"6","author":"Federici","year":"2008","journal-title":"J. Thromb. Haemostasis"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-976169","article-title":"Hemostatic dysfunction in paraproteinemias and amyloidosis","volume":"33","author":"Zangari","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem. J."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34111_bib42","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1074\/jbc.M806010200","article-title":"NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis","volume":"284","author":"Li","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34111_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102720","article-title":"Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release","volume":"11","author":"Gidaro","year":"2022","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34111_bib45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jth.14759","article-title":"Cytokine and chemokine regulation of venous thromboembolism","volume":"18","author":"Najem","year":"2020","journal-title":"J. Thromb. Haemostasis"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34111_bib46","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/jth.15773","article-title":"The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies","volume":"20","author":"Comerford","year":"2022","journal-title":"J. Thromb. Haemostasis : JTH"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34111_bib47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e34111_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.thromres.2023.04.014","article-title":"Elevated von Willebrand factor levels in multiple myeloma: dysregulated mechanisms of both secretion and clearance","volume":"226","author":"Comerford","year":"2023","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/eci.12269","article-title":"Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma","volume":"44","author":"Undas","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e34111_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.thromres.2023.12.004","article-title":"Low factor XIII levels and altered fibrinolysis in patients with multiple myeloma","volume":"234","author":"Ghansah","year":"2023","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e34111_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1538-7836.2009.03410.x","article-title":"The protein C pathway and pathologic processes","volume":"7","author":"Castellino","year":"2009","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.heliyon.2024.e34111_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1118691","article-title":"Obesity and myeloma: clinical and mechanistic contributions to disease progression","volume":"14","author":"Marques-Mourlet","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1681\/ASN.V22191","article-title":"Altered renal calcium handling in hypercalcemia of malignancy","volume":"2","author":"Tuttle","year":"1991","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000505992","article-title":"The association between metabolic syndrome and multiple myeloma","volume":"144","author":"Ragbourne","year":"2021","journal-title":"Acta Haematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2169\/internalmedicine.35.337","article-title":"Hyperlipidemia associated with multiple myeloma","volume":"35","author":"Fukudome","year":"1996","journal-title":"Intern. Med."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e34111_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111430","article-title":"Metabolic disorders in multiple myeloma","volume":"22","author":"Gavriatopoulou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00277-009-0849-9","article-title":"Hyperlipidemic myeloma: review of 53 cases","volume":"89","author":"Misselwitz","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jep.2016.07.023","article-title":"Tongqiaohuoxue decoction ameliorates obesity-induced inflammation and the prothrombotic state by regulating adiponectin and plasminogen activator inhibitor-1","volume":"192","author":"Kim","year":"2016","journal-title":"J. Ethnopharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34111_bib60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/hr.2010.9","article-title":"Mechanisms of obesity-induced hypertension","volume":"33","author":"Kotsis","year":"2010","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrcardio.2009.55","article-title":"Obesity, inflammation, and atherosclerosis","volume":"6","author":"Rocha","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib62","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1055\/s-0038-1657691","article-title":"Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons","volume":"78","author":"Niessen","year":"1997","journal-title":"Thromb. Haemostasis"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e34111_bib63","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib64","first-page":"969","article-title":"Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins","volume":"100","author":"Kruithof","year":"2008","journal-title":"Thromb. Haemostasis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12885-020-06976-1","article-title":"Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma","volume":"20","author":"Markus","year":"2020","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34111_bib66","article-title":"DVT as the initial presentation of multiple myeloma: a rare case report and literature review","volume":"15","author":"Khalil","year":"2023","journal-title":"Cureus"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e34111_bib67","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","article-title":"Update of thrombosis in multiple myeloma","volume":"140","author":"Leebeek","year":"2016","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib72","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34111_bib73","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34111_bib78","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34111_bib84","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Suppl","key":"10.1016\/j.heliyon.2024.e34111_bib87","article-title":"P940: safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 study","volume":"6","author":"Suvannasankha","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib89","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","article-title":"Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34111_bib90","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib91","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","article-title":"Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"186","author":"Jakubowiak","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40487-020-00137-x","article-title":"Daratumumab monotherapy for relapsed or refractory multiple myeloma: results of an early access treatment protocol in Europe and Russia","volume":"9","author":"Cook","year":"2021","journal-title":"Oncol Ther"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34111_bib97","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00277-022-04951-3","article-title":"Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)","volume":"101","author":"Jing","year":"2022","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34111_bib98","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib101","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.26088","article-title":"A phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed\/refractory multiple myeloma: final analysis of second dose-expansion cohort","volume":"96","author":"Berdeja","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000508529","article-title":"Phase II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed or relapsed-and-refractory multiple myeloma","volume":"144","author":"Suzuki","year":"2021","journal-title":"Acta Haematol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34111_bib108","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib112","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","article-title":"A phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma","volume":"124","author":"Lendvai","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e34111_bib115","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e34111_bib116","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e34111_bib68","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib70","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.2147\/OTT.S223697","article-title":"Coexistence of A huge venous thromboembolism and bleeding tendency in cytokine release syndrome during CAR-T therapy","volume":"12","author":"Liu","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.898341","article-title":"Case report: ITP treatment after CAR-T cell therapy in patients with multiple myeloma","volume":"13","author":"Du","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34111_bib75","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2024.e34111_bib76","doi-asserted-by":"crossref","unstructured":"Roussel M, Texier N, Nael V, Bitetti J, Paka P, Kerbouche N, Sail L, Colin X, Leleu X. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study. Eur J Haematol. 2024 May 9. doi: 10.1111\/ejh.14222. Epub ahead of print.","DOI":"10.1111\/ejh.14222"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34111_bib77","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14712598.2023.2218543","article-title":"Belantamab mafodotin in multiple myeloma","volume":"23","author":"Martino","year":"2023","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.heliyon.2024.e34111_bib80","first-page":"529","article-title":"Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of triple class refractory multiple myeloma","volume":"12","author":"Neupane","year":"2021","journal-title":"Hematol. Res. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib81","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.17448","article-title":"Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: cohort 2 of the phase I KEYNOTE-023 study","volume":"194","author":"Moreau","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib82","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib83","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3389\/fimmu.2018.02749","article-title":"Promises and pitfalls in the use of PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Oliva","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34111_bib85","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.2147\/CMAR.S338023","article-title":"Vascular thrombosis and anti-PD-1 therapy: a series of cases","volume":"13","author":"Fu","year":"2021","journal-title":"Cancer Manag. Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34111_bib86","doi-asserted-by":"crossref","first-page":"E430","DOI":"10.1002\/ajh.26333","article-title":"Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma","volume":"96","author":"Biran","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34111_bib88","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34111_bib92","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","article-title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34111_bib93","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the treatment of multiple myeloma","volume":"21","author":"Podar","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34111_bib94","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/10428194.2021.1910687","article-title":"Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials","volume":"62","author":"Wang","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e34111_bib95","doi-asserted-by":"crossref","first-page":"12952","DOI":"10.1074\/jbc.M110.207100","article-title":"Critical role for CD38-mediated Ca2+ signaling in thrombin-induced procoagulant activity of mouse platelets and hemostasis","volume":"286","author":"Mushtaq","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34111_bib99","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 Years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-021-00407-5","article-title":"Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed\/refractory multiple myeloma","volume":"11","author":"Laubach","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34111_bib103","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.exphem.2012.02.004","article-title":"Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation","volume":"40","author":"Iancu-Rubin","year":"2012","journal-title":"Exp. Hematol."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e34111_bib104","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e34111_bib105","article-title":"Efficacy of panobinostat for the treatment of multiple myeloma","volume":"2020","author":"Eleutherakis-Papaiakovou","year":"2020","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34111_bib106","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e34111_bib107","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2019003749","article-title":"Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia","volume":"135","author":"Tochigi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e34111_bib109","first-page":"1","article-title":"Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma","volume":"9","author":"Nomura","year":"2018","journal-title":"Hematol. Res. Rev."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib110","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.12522","article-title":"Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma","volume":"93","author":"Zangari","year":"2008","journal-title":"Haematologica"},{"issue":"Suppl 3","key":"10.1016\/j.heliyon.2024.e34111_bib111","first-page":"S56","article-title":"Simultaneous cases of carfilzomib-induced thrombotic microangiopathy in 2 patients with multiple myeloma, federal practitioner : for the health care professionals of the VA","volume":"39","author":"Myall","year":"2022","journal-title":"DoD, and PHS"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34111_bib113","doi-asserted-by":"crossref","first-page":"274","DOI":"10.14740\/jmc3932","article-title":"Carfilzomib-induced thrombotic microangiopathy: focus on pathogenesis","volume":"13","author":"Eigbire-Molen","year":"2022","journal-title":"J. Med. Cases"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34111_bib114","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34111_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229312","article-title":"Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma","volume":"12","author":"Siddiq","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e34111_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246216","article-title":"Approach to contemporary risk assessment, prevention and management of thrombotic complications in multiple myeloma","volume":"14","author":"Fotiou","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib120","first-page":"363","article-title":"Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy","author":"Covut","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program 2022"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34111_bib121","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34111_bib122","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","journal-title":"J. Thromb. Haemostasis"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34111_bib123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ijc.32109","article-title":"Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies","volume":"145","author":"Psaltopoulou","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34111_bib124","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ejca.2011.01.020","article-title":"Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies","volume":"47","author":"Wallin","year":"2011","journal-title":"Eur. J. Cancer"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024101429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024101429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:02:31Z","timestamp":1778886151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024101429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":124,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024101429"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34111","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rediscovering hemostasis abnormalities in multiple myeloma: The new era","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34111"}}